Lancashire and South Cumbria
Formulary
6 Endocrine system
06-06-02 Bisphosphonates and other drugs affecting bone metabolism
Romosozumab
Evenity
®
Formulary
Solution for injection in pre-filled pen 105mg
NICE TA791: Romosozumab for treating severe osteoporosis
Links
LSCMMG: Denosumab as a second line treatment option for the prevention of osteoporotic fragility fractures position statement
LSCMMG: Ibandronic acid tablets
LSCMMG: Shared care guideline (Denosumab 120mg injection (Xgeva®))
LSCMMG: Shared care guideline (Denosumab 60mg injection (Prolia®))
MHRA Drug Safety Update Aug 2020: Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment
MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal
MHRA Drug Safety Update June 2017: Denosumab (Prolia, Xgeva): reports of osteonecrosis of the external auditory canal
MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate
MHRA Drug Safety Update June 2018: Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation
MHRA Drug Safety Update May 2022: Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia
MHRA safety update Dec 2014:Rare cases of atypical femoral fracture with long-term use
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: atypical femoral fractures
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: osteonecrosis of the jaw
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
MHRA: Denosumab: updated recommendations
MHRA: Denosumab: updated recommendations
MHRA: Strontium: cardiovascular risk—restricted indication and new monitoring requirements
NICE TA204: Osteoporotic fractures - denosumab
NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
NICE TA464: Bisphosphonates for treating osteoporosis
NICE TA791: Romosozumab for treating severe osteoporosis
Osteoporosis Guideline (NOGG 2021)
Key
Full Site